top of page
Vitamins

Safety and Well-being

What is a contraindication?

An absolute contraindication is something that cannot be used under any circumstance due to the high level of risk. 

Medical contraindications

Psychedelics are contraindicated if someone is pregnant, or has a history of epilepsy/other seizure disorder, or severe cardiovascular disease including uncontrolled blood pressure, heart failure, coronary artery disease or previous heart attack or stroke [3].

 

Psychedelics  are contraindicated in people using medications like SSRI or MAO-I antidepressants who are not able to be weaned off of these medications before treatment [3].

Psychiatric contraindications

Psychedelics can be dangerous for people who have a personal or family history of primary psychotic or affective disorders like Schizophrenia, Schizoaffective disorder, or Bipolar 1 disorder.  It can also be dangerous for people who experience psychotic symptoms in the setting of depression. This is because it can increase the risk of psychotic episodes in these groups of people [3].

People with significant trauma histories who have not yet learned fundamental coping skills or developed a safety plan (e.g. the stabilisation phase of trauma treatment) should not take psychedelics for the same reason they should not engage in therapies like cognitive processing therapy or prolonged exposure. Psychedelics can lead to reliving traumatic experiences, and opening up repressed traumatic memories that can lead to significant emotional upheaval that can have [4].

Similarly, psychedelics are contraindicated in people who’ve previously experienced any adverse effect from these substance such as prolonged psychosis or suicidal ideation [3].

Conclusion

If you are considering taking part in a retreat where psilocybin is offered, you should make sure you contact a medical specialist if you are unsure about your personal situation. 

Source and References

Source

  1. Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019 May;197:83-102. doi: 10.1016/j.pharmthera.2018.11.010. Epub 2018 Dec 4. PMID: 30521880.

  2. Jacob S. Aday, Cayla M. Mitzkovitz, Emily K. Bloesch, Christopher C. Davoli, Alan K. Davis, Long-term effects of psychedelic drugs: A systematic review, Neuroscience & Biobehavioral Reviews, Volume 113, 2020, Pages 179-189, ISSN 0149-7634, https://doi.org/10.1016/j.neubiorev.2020.03.017.

  3. Frecska, Ede. (2007). Therapeutic guidelines: dangers and contra-indications in therapeutic applications of hallucinogens. 10.13140/RG.2.1.2364.8888.

  4. Erwin Krediet, Tijmen Bostoen, Joost Breeksema, Annette van Schagen, Torsten Passie, Eric Vermetten, Reviewing the Potential of Psychedelics for the Treatment of PTSD, International Journal of Neuropsychopharmacology, Volume 23, Issue 6, June 2020, Pages 385–400, https://doi.org/10.1093/ijnp/pyaa018

Subscribe to our newsletter and get updates about upcoming retreats

Thanks we will keep you in the loop!

bottom of page